Literature DB >> 22795355

The composition of the microenvironment in follicular lymphoma is associated with the stage of the disease.

Karoline Koch1, Eva Hoster, Michael Unterhalt, German Ott, Andreas Rosenwald, Martin L Hansmann, Marianne Engelhard, Wolfgang Hiddemann, Wolfram Klapper.   

Abstract

The role of regulatory and follicular helper T-cells as prognostic markers in follicular lymphoma was evaluated within the setting of prospective, randomized trials because the previously published results were contradictory. Two hundred sixty-four diagnostic tissue specimens from patients suffering from follicular lymphoma who received therapy within prospective randomized trials of the German Low Grade Lymphoma Study Group were analyzed immunohistochemically for FoxP3 and PD-1 expression to detect regulatory and follicular helper T-cells, respectively. We did not find any correlation between the content of regulatory and follicular helper T-cells and the time to treatment failure or overall survival in patients with advanced stages of follicular lymphoma in need of treatment. However, a perifollicular pattern of regulatory T-cells was associated with a poorer prognosis. The content of regulatory T-cells was positively and the content of follicular helper T-cells inversely correlated with a higher stage of the disease at diagnosis, implying that the microenvironment changes during tumor dissemination. This finding is independent of any therapy administered and needs to be considered when possible biomarkers related to the microenvironment of follicular lymphoma are studied.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22795355     DOI: 10.1016/j.humpath.2012.03.025

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  10 in total

1.  Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.

Authors:  Jason R Westin; Fuliang Chu; Min Zhang; Luis E Fayad; Larry W Kwak; Nathan Fowler; Jorge Romaguera; Fredrick Hagemeister; Michelle Fanale; Felipe Samaniego; Lei Feng; Veerabhadran Baladandayuthapani; Zhiqiang Wang; Wencai Ma; Yanli Gao; Michael Wallace; Luis M Vence; Laszlo Radvanyi; Tariq Muzzafar; Rinat Rotem-Yehudar; R Eric Davis; Sattva S Neelapu
Journal:  Lancet Oncol       Date:  2013-12-11       Impact factor: 41.316

2.  Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus.

Authors:  E Leich; E Hoster; M Wartenberg; M Unterhalt; R Siebert; K Koch; W Klapper; M Engelhard; B Puppe; H Horn; A M Staiger; C Stuhlmann-Laeisz; H W Bernd; A C Feller; M Hummel; D Lenze; H Stein; S Hartmann; M L Hansmann; P Möller; W Hiddemann; M Dreyling; G Ott; A Rosenwald
Journal:  Leukemia       Date:  2015-12-01       Impact factor: 11.528

Review 3.  Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?

Authors:  Fabienne McClanahan; Thomas G Sharp; John G Gribben
Journal:  Haematologica       Date:  2016-10       Impact factor: 9.941

4.  Lectins from opportunistic bacteria interact with acquired variable-region glycans of surface immunoglobulin in follicular lymphoma.

Authors:  Dunja Schneider; Marcus Dühren-von Minden; Alabbas Alkhatib; Corinna Setz; Cornelis A M van Bergen; Marco Benkißer-Petersen; Isabel Wilhelm; Sarah Villringer; Sergey Krysov; Graham Packham; Katja Zirlik; Winfried Römer; Christian Buske; Freda K Stevenson; Hendrik Veelken; Hassan Jumaa
Journal:  Blood       Date:  2015-03-17       Impact factor: 22.113

5.  Dissecting the regulatory microenvironment of a large animal model of non-Hodgkin lymphoma: evidence of a negative prognostic impact of FOXP3+ T cells in canine B cell lymphoma.

Authors:  Dammy Pinheiro; Yu-Mei Chang; Hannah Bryant; Balazs Szladovits; Tim Dalessandri; Lucy J Davison; Elizabeth Yallop; Emily Mills; Chiara Leo; Ana Lara; Anneliese Stell; Gerry Polton; Oliver A Garden
Journal:  PLoS One       Date:  2014-08-13       Impact factor: 3.240

6.  Automated prognostic pattern detection shows favourable diffuse pattern of FOXP3(+) Tregs in follicular lymphoma.

Authors:  Lilli S Nelson; James R Mansfield; Roslyn Lloyd; Kenneth Oguejiofor; Zena Salih; Lia P Menasce; Kim M Linton; Chris J Rose; Richard J Byers
Journal:  Br J Cancer       Date:  2015-10-06       Impact factor: 7.640

7.  Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium.

Authors:  Wendy B C Stevens; Matias Mendeville; Robert Redd; Andrew J Clear; Reno Bladergroen; Maria Calaminici; Andreas Rosenwald; Eva Hoster; Wolfgang Hiddemann; Philippe Gaulard; Luc Xerri; Gilles Salles; Wolfram Klapper; Michael Pfreundschuh; Andrew Jack; Randy D Gascoyne; Yasodha Natkunam; Ranjana Advani; Eva Kimby; Birgitta Sander; Laurie H Sehn; Anton Hagenbeek; John Raemaekers; John Gribben; Marie José Kersten; Bauke Ylstra; Edie Weller; Daphne de Jong
Journal:  Haematologica       Date:  2017-04-14       Impact factor: 9.941

8.  Molecular Cytogenetic Profiling Reveals Similarities and Differences Between Localized Nodal and Systemic Follicular Lymphomas.

Authors:  Heike Horn; Vindi Jurinovic; Ellen Leich; Sabrina Kalmbach; Julia Bausinger; Annette M Staiger; Katrin S Kurz; Peter Möller; Heinz-Wolfram Bernd; Alfred C Feller; Karoline Koch; Wolfram Klapper; Harald Stein; Martin-Leo Hansmann; Sylvia Hartmann; Gabriel Scheubeck; Martin Dreyling; Wolfgang Hiddemann; Klaus Herfarth; Marianne Engelhard; Andreas Rosenwald; Eva Hoster; German Ott
Journal:  Hemasphere       Date:  2022-08-10

Review 9.  Recent insights in the pathogenesis of post-transplantation lymphoproliferative disorders.

Authors:  Julie Morscio; Thomas Tousseyn
Journal:  World J Transplant       Date:  2016-09-24

10.  Sites of extranodal involvement are prognostic in patients with stage 1 follicular lymphoma.

Authors:  Aditi Shastri; Murali Janakiram; Ioannis Mantzaris; Yiting Yu; Jaime S Londono; Amit K Verma; Stefan K Barta
Journal:  Oncotarget       Date:  2017-07-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.